The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Open accessAbstract
Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults and remains incurable despite multimodal intensive treatment regimens. EGFRvIII is a truncated extracellular mutant of the EGF receptor (EGFR) commonly found in GBMs that confers enhanced tumorigenic behavior. To gain a molecular understanding of the mechanisms by which EGFRvIII acts, we have performed a large-scale analysis of EGFRvIII-activated phosphotyrosine-mediated signaling pathways and thereby have identified and quantified 99 phosphorylation sites on 69 proteins. Distinct signaling responses were observed as a function of titrated EGFRvIII receptor levels with the phosphatidylinositol 3-kinase pathway being dominant over the MAPK and STAT3 pathways at a high level of EGFRvIII expression. Within this data set, the activating phosphorylation site on the c-Met receptor was found to be highly responsive to EGFRvIII levels, indicating cross-activation of the c-Met receptor tyrosine kinase by EGFRvIII. To determine the significance of this finding, we devised a combined treatment regimen that used a c-Met kinase inhibitor and either an EGFR kinase inhibitor or cisplatin. This regimen resulted in enhanced cytotoxicity of EGFRvIII-expressing cells compared with treatment with either compound alone. These results suggest that the clinical use of c-Met kinase inhibitors in combination with either EGFR inhibitors or standard chemotherapeutics might represent a previously undescribed therapeutic approach to overcome the observed chemoresistance in patients with GBMs expressing EGFRvIII.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Self-citationMalignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229
Self-citationA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Self-citationHuang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595
Self-citationA dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Zhang, Y., Wolf-Yadlin, A., Ross, P. L., Pappin, D. J., Rush, J., Lauffenburger, D. A., & White, F. M. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500089-mcp200 · Cited by 541
Self-citationChristensen, J. G., Schreck, R., Burrows, J., Kuruganti, P. A., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R. A., et al. (2003) · PubMed · Cited by 497
Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608638104 · Cited by 493
Self-citationFurnari, F. B., Huang, H., & Cavenee, W. K. (1998) · PubMed · Cited by 395
Self-citationNagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., & Huang, H.-J. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5724 · Cited by 363
Self-citationMet and hepatocyte growth factor/scatter factor expression in human gliomas.
Koochekpour, S., Jeffers, M., Rulong, S., Taylor, G., Klineberg, E. O., Hudson, E. A., Resau, J. H., & Woude, G. F. V. (1997) · PubMed · Cited by 320
Moscatello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, R. B., & Wong, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.200 · Cited by 305
Wang, M. Y., Lu, K. V., Zhu, S., Dia, E. Q., Vivanco, I., Shackleford, G. M., Cavenee, W. K., Mellinghoff, I. K., Cloughesy, T. F., Sawyers, C. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4392 · Cited by 240
Self-citationBindingDB (2025) · PubMed · doi:10.7270/q2dv1qm3 · Cited by 235
From Tpr-Met to Met, tumorigenesis and tubes
Peschard, P., & Park, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210201 · Cited by 180
Epidermal growth factor receptor family (EGFR, ErbB2?4) in gliomas and meningiomas
Andersson, U., Guo, D., Malmer, B., Bergenheim, A. T., Brnnstrm, T., Hedman, H., & Henriksson, R. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0875-6 · Cited by 169
Bowers, D. C., Fan, S., Walter, K. A., Abounader, R., Williams, J. A., Rosen, E. M., & Laterra, J. (2000) · PubMed · Cited by 168
Amplification and differential expression of members of theerbB-gene family in human glioblastoma
Schlegel, J., Stumm, G., Br�ndle, K., Merdes, A., Mechtersheimer, G., Hynes, N. E., & Kiessling, M. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052920 · Cited by 112
Johns, T. G., Perera, R. M., Vernes, S. C., Vitali, A. A., Cao, D. X., Cavenee, W. K., Scott, A. M., & Furnari, F. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1453 · Cited by 84
Self-citationNagane, M., Narita, Y., Mishima, K., Levitzki, A., Burgess, A. W., Cavenee, W. K., & Huang, H. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.3.0472 · Cited by 83
Self-citationChattopadhyay, N., Butters, R. R., & Brown, E. M. (2001) · Molecular Brain Research · doi:10.1016/s0165-3806(00)00154-1 · Cited by 47
Cited by
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“Another study (Huang et al. 2007) showed that glioma cells engineered to overexpress EGFRvIII to levels observed in GBM caused increased c-MET phosphorylation that was dependent on the kinase activity and levels of this mutant EGFR.”
BackgroundSelf-citationCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
The biological impact of mass-spectrometry-based proteomics
Cravatt, B. F., Simon, G. M., & Yates III, J. R. (2007) · Nature · doi:10.1038/nature06525 · Cited by 705
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Harrison, P. T., Vyse, S., & Huang, P. H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.015 · Cited by 615
Self-citation
Metadata
- Authors
- Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-07-31
- Volume
- 104
- Issue
- 31
- Pages
- 12867-12872
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1978177843
- Cited by
- 390
- References
- 23
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.